About: covid:PMC7273162

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7273162 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Walker, Paul Costa, Daniel Gill, Ritu Brody, Heather Bulumulle, Anushi Cherry, Cynthia Huberman, Mark Macherla, Shravanti McDonald, Danielle Qilleri, Aleksandra Rangachari, Deepa Sehgal, Kartik Shea, Meghan VanderLaan, Paul Weiss, Glen
is schema:about of	named entity 'non-small cell lung cancer' named entity 'statistically significant' named entity 'VMC' named entity 'pembrolizumab' named entity '2.6' named entity 'fluorescence in-situ hybridization' named entity '2C-D' named entity 'pharmacodynamic' named entity 'cancer centers' named entity 'non-small cell lung cancer' named entity 'pembrolizumab' named entity 'univariate analysis' named entity 'NSCLC' named entity 'clinical trials' named entity 'pembrolizumab' named entity 'Association' named entity 'advanced' named entity 'Bayesian methods' named entity 'clinical trials' named entity 'Harvard Medical School' named entity 'pembrolizumab' named entity 'plasma or serum' named entity 'NSCLC' named entity 'NSCLC' named entity 'multiple comparisons' named entity 'PFS' named entity 'pembrolizumab' named entity 'monotherapy' named entity 'PFS' named entity '1.2' named entity 'medical issues' named entity 'radiologists' named entity 'FDA' named entity 'pharmacokinetic' named entity 'retrospective cohort study' named entity 'pembrolizumab' named entity 'institutional review boards' named entity 'pembrolizumab' named entity 'survival analysis' named entity 'pembrolizumab' named entity 'pembrolizumab' named entity 'BIDMC' named entity 'FDA' named entity 'confounding factors' named entity 'cancer centers' named entity 'pembrolizumab' named entity 'medical issues' named entity 'stage IV' named entity 'Beth Israel Deaconess Medical Center' named entity 'PFS' named entity 'clinical trials' named entity 'pembrolizumab' named entity 'next-generation sequencing' named entity 'therapeutic drug monitoring' named entity 'adverse events' named entity 'palliative care' named entity 'Univariate' named entity 'tumor' named entity 'confounding variables' named entity 'FDA' named entity 'chemotherapy' named entity 'clinical trials' named entity 'pembrolizumab' named entity 'Kaplan-Meier' named entity 'immunosuppressive agents' named entity 'Stata' named entity 'Microsoft Excel' named entity 'polymerase chain reaction' named entity 'pembrolizumab' named entity 'NSCLC' named entity 'Univariate' named entity 'pembrolizumab' named entity 'pembrolizumab' named entity 'European Commission' named entity 'toxicity' named entity 'Response Evaluation Criteria in Solid Tumors' named entity 'NSCLC' named entity 'NSCLC' named entity 'therapeutic drug monitoring' named entity 'prospective studies' named entity 'progression-free survival' named entity 'Brody School of Medicine at East Carolina University' named entity 'pembrolizumab' named entity 'pembrolizumab' named entity 'sample size'

Attributes

Values

Creator

Walker, Paul
Costa, Daniel
Gill, Ritu
Brody, Heather
Bulumulle, Anushi
Cherry, Cynthia
Huberman, Mark
Macherla, Shravanti
McDonald, Danielle
Qilleri, Aleksandra
Rangachari, Deepa
Sehgal, Kartik
Shea, Meghan
VanderLaan, Paul
Weiss, Glen

is schema:about of

named entity 'non-small cell lung cancer'
named entity 'statistically significant'
named entity 'VMC'
named entity 'pembrolizumab'
named entity '2.6'
named entity 'fluorescence in-situ hybridization'
named entity '2C-D'
named entity 'pharmacodynamic'
named entity 'cancer centers'
named entity 'non-small cell lung cancer'
named entity 'pembrolizumab'
named entity 'univariate analysis'
named entity 'NSCLC'
named entity 'clinical trials'
named entity 'pembrolizumab'
named entity 'Association'
named entity 'advanced'
named entity 'Bayesian methods'
named entity 'clinical trials'
named entity 'Harvard Medical School'
named entity 'pembrolizumab'
named entity 'plasma or serum'
named entity 'NSCLC'
named entity 'NSCLC'
named entity 'multiple comparisons'
named entity 'PFS'
named entity 'pembrolizumab'
named entity 'monotherapy'
named entity 'PFS'
named entity '1.2'
named entity 'medical issues'
named entity 'radiologists'
named entity 'FDA'
named entity 'pharmacokinetic'
named entity 'retrospective cohort study'
named entity 'pembrolizumab'
named entity 'institutional review boards'
named entity 'pembrolizumab'
named entity 'survival analysis'
named entity 'pembrolizumab'
named entity 'pembrolizumab'
named entity 'BIDMC'
named entity 'FDA'
named entity 'confounding factors'
named entity 'cancer centers'
named entity 'pembrolizumab'
named entity 'medical issues'
named entity 'stage IV'
named entity 'Beth Israel Deaconess Medical Center'
named entity 'PFS'
named entity 'clinical trials'
named entity 'pembrolizumab'
named entity 'next-generation sequencing'
named entity 'therapeutic drug monitoring'
named entity 'adverse events'
named entity 'palliative care'
named entity 'Univariate'
named entity 'tumor'
named entity 'confounding variables'
named entity 'FDA'
named entity 'chemotherapy'
named entity 'clinical trials'
named entity 'pembrolizumab'
named entity 'Kaplan-Meier'
named entity 'immunosuppressive agents'
named entity 'Stata'
named entity 'Microsoft Excel'
named entity 'polymerase chain reaction'
named entity 'pembrolizumab'
named entity 'NSCLC'
named entity 'Univariate'
named entity 'pembrolizumab'
named entity 'pembrolizumab'
named entity 'European Commission'
named entity 'toxicity'
named entity 'Response Evaluation Criteria in Solid Tumors'
named entity 'NSCLC'
named entity 'NSCLC'
named entity 'therapeutic drug monitoring'
named entity 'prospective studies'
named entity 'progression-free survival'
named entity 'Brody School of Medicine at East Carolina University'
named entity 'pembrolizumab'
named entity 'pembrolizumab'
named entity 'sample size'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software